Multi-wavelength continuous-wave self-Raman laser with an a-cut composite YVO4/Nd:YVO4/YVO4 crystal pumped by an 879-nm wavelength-locked laser diode is demonstrated for the first time.Multi-wavelength Raman lasers at...Multi-wavelength continuous-wave self-Raman laser with an a-cut composite YVO4/Nd:YVO4/YVO4 crystal pumped by an 879-nm wavelength-locked laser diode is demonstrated for the first time.Multi-wavelength Raman lasers at 1168.4,1176,1178.7,and 1201.6 nm are achieved by the first Stokes shift of the multi-wavelength fundamental lasers at 1064,1066.7,1073.6,1084,and 1085.6 nm with two Raman shifts of 890 and 816 cm^-1.A maximum Raman output power of 2.56 W is achieved through the use of a 20-mm-long composite crystal,with a corresponding optical conversion efficiency of 9.8%.The polarization directions of different fundamental and Raman lasers are investigated and found to be orthogonalπandσpolarizations.These orthogonally polarized multi-wavelength lasers with small wavelength separation pave the way to the development of a potential laser source for application in spectral analysis,laser radar and THz generation.展开更多
目的:评价还原汤治疗急性脑梗死的临床疗效及其对患者血清炎症因子IL-6、TNF-α和hs-CRP水平的影响。方法:将符合标准的100例急性脑梗死患者随机分为治疗组和对照组,每组各50例。两组患者均给予西医常规治疗,治疗组在常规治疗基础上加...目的:评价还原汤治疗急性脑梗死的临床疗效及其对患者血清炎症因子IL-6、TNF-α和hs-CRP水平的影响。方法:将符合标准的100例急性脑梗死患者随机分为治疗组和对照组,每组各50例。两组患者均给予西医常规治疗,治疗组在常规治疗基础上加用还原汤口服,治疗周期为15 d。比较两组患者的临床疗效;治疗前后及发病90 d随访时,采用美国国立卫生研究院卒中量表(National Institute of Health stroke scale,NIHSS)评分评价患者的神经功能缺损程度,采用Barthel指数(Barthel index,BI)和改良Rankin量表(modified Rankin scale,mRS)评分评定患者的生活质量;治疗前后检测两组患者的IL-6、TNF-α和hs-CRP水平。结果:治疗后,治疗组和对照组的临床总有效率分别为83.7%和55.3%,治疗组的疗效优于对照组(P<0.01)。与治疗前比较,治疗后及随访时,治疗组患者的NIHSS、mRS评分显著降低(P<0.01),BI评分显著升高(P<0.01),对照组患者的NIHSS评分亦显著降低(P<0.01),且随访时,对照组患者的mRS评分显著降低(P<0.01)、BI评分显著升高(P<0.01)。与治疗后比较,随访时,两组患者的NIHSS评分均降低(P<0.05),且治疗组患者的BI评分明显升高(P<0.05)、mRS评分显著降低(P<0.05)。与对照组比较,治疗后及随访时,治疗组患者的NIHSS、mRS评分均显著降低(P<0.01,P<0.05),BI评分显著升高(P<0.01,P<0.05)。治疗后,两组患者的IL-6、TNF-α、hs-CRP水平较治疗前均明显下降(P<0.01),且治疗组患者的IL-6、TNF-α、hs-CRP水平低于对照组(P<0.05,P<0.01)。结论:还原汤结合西医常规疗法治疗急性脑梗死,能够有效改善患者的临床症状和体征,提高其生活质量及远期疗效,并能降低患者的血清炎症因子水平。展开更多
基金Project supported by the National Natural Science Foundation of China(Grant No.11774301)the Young Scientists Fund of the National Natural Science Foundation of China(Grant No.11804292)
文摘Multi-wavelength continuous-wave self-Raman laser with an a-cut composite YVO4/Nd:YVO4/YVO4 crystal pumped by an 879-nm wavelength-locked laser diode is demonstrated for the first time.Multi-wavelength Raman lasers at 1168.4,1176,1178.7,and 1201.6 nm are achieved by the first Stokes shift of the multi-wavelength fundamental lasers at 1064,1066.7,1073.6,1084,and 1085.6 nm with two Raman shifts of 890 and 816 cm^-1.A maximum Raman output power of 2.56 W is achieved through the use of a 20-mm-long composite crystal,with a corresponding optical conversion efficiency of 9.8%.The polarization directions of different fundamental and Raman lasers are investigated and found to be orthogonalπandσpolarizations.These orthogonally polarized multi-wavelength lasers with small wavelength separation pave the way to the development of a potential laser source for application in spectral analysis,laser radar and THz generation.
文摘目的:评价还原汤治疗急性脑梗死的临床疗效及其对患者血清炎症因子IL-6、TNF-α和hs-CRP水平的影响。方法:将符合标准的100例急性脑梗死患者随机分为治疗组和对照组,每组各50例。两组患者均给予西医常规治疗,治疗组在常规治疗基础上加用还原汤口服,治疗周期为15 d。比较两组患者的临床疗效;治疗前后及发病90 d随访时,采用美国国立卫生研究院卒中量表(National Institute of Health stroke scale,NIHSS)评分评价患者的神经功能缺损程度,采用Barthel指数(Barthel index,BI)和改良Rankin量表(modified Rankin scale,mRS)评分评定患者的生活质量;治疗前后检测两组患者的IL-6、TNF-α和hs-CRP水平。结果:治疗后,治疗组和对照组的临床总有效率分别为83.7%和55.3%,治疗组的疗效优于对照组(P<0.01)。与治疗前比较,治疗后及随访时,治疗组患者的NIHSS、mRS评分显著降低(P<0.01),BI评分显著升高(P<0.01),对照组患者的NIHSS评分亦显著降低(P<0.01),且随访时,对照组患者的mRS评分显著降低(P<0.01)、BI评分显著升高(P<0.01)。与治疗后比较,随访时,两组患者的NIHSS评分均降低(P<0.05),且治疗组患者的BI评分明显升高(P<0.05)、mRS评分显著降低(P<0.05)。与对照组比较,治疗后及随访时,治疗组患者的NIHSS、mRS评分均显著降低(P<0.01,P<0.05),BI评分显著升高(P<0.01,P<0.05)。治疗后,两组患者的IL-6、TNF-α、hs-CRP水平较治疗前均明显下降(P<0.01),且治疗组患者的IL-6、TNF-α、hs-CRP水平低于对照组(P<0.05,P<0.01)。结论:还原汤结合西医常规疗法治疗急性脑梗死,能够有效改善患者的临床症状和体征,提高其生活质量及远期疗效,并能降低患者的血清炎症因子水平。
